These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 7704089

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
    Grill V, Murray RM, Ho PW, Santamaria JD, Pitt P, Potts C, Jerums G, Martin TJ.
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
    [Abstract] [Full Text] [Related]

  • 4. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ.
    Cancer; 1994 Apr 15; 73(8):2223-30. PubMed ID: 8156530
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE.
    Am J Med; 1993 Sep 15; 95(3):297-304. PubMed ID: 8368227
    [Abstract] [Full Text] [Related]

  • 7. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.
    Jansson S, Morgan E.
    World J Surg; 2004 Dec 15; 28(12):1293-7. PubMed ID: 15517486
    [Abstract] [Full Text] [Related]

  • 8. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M, Janisch S, Marosi C, Wogritsch C, Bosse C, Schratzberger W, Gerber E, Fortelny A, Lenzhofer R, Rainer H.
    Klin Wochenschr; 1991 Oct 02; 69(15):690-5. PubMed ID: 1795492
    [Abstract] [Full Text] [Related]

  • 9. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
    Gurney H, Grill V, Martin TJ.
    Lancet; 1993 Jun 26; 341(8861):1611-3. PubMed ID: 8099988
    [Abstract] [Full Text] [Related]

  • 10. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
    Tal A, Graves L.
    South Med J; 1996 Jun 26; 89(6):637-40. PubMed ID: 8638211
    [Abstract] [Full Text] [Related]

  • 11. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
    Budayr AA, Zysset E, Jenzer A, Thiébaud D, Ammann P, Rizzoli R, Jaquet-Müller F, Bonjour JP, Gertz B, Burckhardt P.
    J Bone Miner Res; 1994 Apr 26; 9(4):521-6. PubMed ID: 8030440
    [Abstract] [Full Text] [Related]

  • 12. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
    Body JJ, Dumon JC, Thirion M, Cleeren A.
    J Bone Miner Res; 1993 Jun 26; 8(6):701-6. PubMed ID: 8328312
    [Abstract] [Full Text] [Related]

  • 13. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
    Jansson S, Tisell LE, Lindstedt G, Lundberg PA.
    Surgery; 1991 Sep 26; 110(3):480-6. PubMed ID: 1845370
    [Abstract] [Full Text] [Related]

  • 14. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
    Sekine M, Takami H.
    Oncol Rep; 1998 Sep 26; 5(1):197-9. PubMed ID: 9458321
    [Abstract] [Full Text] [Related]

  • 15. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
    Blind E, Raue F, Meinel T, Wüster C, Ziegler R.
    Horm Metab Res; 1993 Jan 26; 25(1):40-4. PubMed ID: 8428711
    [Abstract] [Full Text] [Related]

  • 16. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
    Schilling T, Pecherstorfer M, Blind E, Leidig G, Ziegler R, Raue F.
    J Clin Endocrinol Metab; 1993 Mar 26; 76(3):801-3. PubMed ID: 8445039
    [Abstract] [Full Text] [Related]

  • 17. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
    Fukumoto S, Matsumoto T, Takebe K, Onaya T, Eto S, Nawata H, Ogata E.
    J Clin Endocrinol Metab; 1994 Jul 26; 79(1):165-70. PubMed ID: 8027221
    [Abstract] [Full Text] [Related]

  • 18. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
    Thiébaud D, Portmann L, Jaeger P, Jacquet AF, Burckhardt P.
    Bone; 1986 Jul 26; 7(4):247-53. PubMed ID: 3768203
    [Abstract] [Full Text] [Related]

  • 19. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
    Gallacher SJ, Fraser WD, Logue FC, Dryburgh FJ, Cowan RA, Boyle IT, Ralston SH.
    Calcif Tissue Int; 1992 Dec 26; 51(6):419-23. PubMed ID: 1333351
    [Abstract] [Full Text] [Related]

  • 20. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
    Rizzoli R, Thiébaud D, Bundred N, Pecherstorfer M, Herrmann Z, Huss HJ, Rückert F, Manegold C, Tubiana-Hulin M, Steinhauer EU, Degardin M, Thürlimann B, Clemens MR, Eghbali H, Body JJ.
    J Clin Endocrinol Metab; 1999 Oct 26; 84(10):3545-50. PubMed ID: 10522993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.